Predictive value of HIV-1 viral load on risk for opportunistic infection

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):154-8. doi: 10.1097/00042560-200206010-00003.

Abstract

Objective: The relationship between HIV-1 viral load and the risk for opportunistic infection (OI) was examined in Adult AIDS Clinical Trial Group (AACTG) 722, a virology substudy of AACTG 323: a phase 4 randomized study designed to examine the use of chronic suppressive versus episodic fluconazole therapy.

Methods: The primary analysis used a case-control sampling scheme with two controls per "case" (subjects that developed an OI) matched by gender, age, and time on study. Forty-five cases and matched controls were identified and used in the analysis.

Results: Study 722 accrued 518 subjects between 5/97 and 11/99. Forty-five subjects developed serious OIs or refractory candidiasis. Median baseline CD4 count was 24 cell/mm3 for cases and 46 for controls (p =.003). Median viral load (VL) was 5.02 log10 copies/mL for cases and 4.08 for controls (p =.002). Multivariate analysis found four independent variables associated with time to OI: baseline VL and CD4 (RR = 2.2 per log increment and 6.0 per 50-cell increment, respectively), a one log increase in VL at any time (RR = 15), and history of an OI (RR = 5.2).

Conclusions: VL and changes in VL were independently associated with risk of development of OIs in a prospective study and should be considered by clinicians when assessing patients for risk of OI.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase IV
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS-Related Opportunistic Infections / diagnosis
  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / etiology*
  • Adult
  • Antifungal Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Candidiasis, Oral / diagnosis
  • Candidiasis, Oral / drug therapy
  • Candidiasis, Oral / etiology
  • Case-Control Studies
  • Female
  • Fluconazole / therapeutic use
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV-1 / physiology*
  • Humans
  • Male
  • Predictive Value of Tests
  • RNA, Viral / blood*
  • Risk Factors
  • Viral Load*

Substances

  • Antifungal Agents
  • RNA, Viral
  • Fluconazole